Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The prognostic and predictive values of ECD-HER-2
Autore:
Hait, WN;
Indirizzi:
UMDNJ, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, New Brunswick, NJ 08903 USA UMDNJ New Brunswick NJ USA 08903 New Jersey, New Brunswick, NJ 08903 USA UMDNJ, Robert Wood Johnson Med Sch, Dept Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08903 USA UMDNJ New Brunswick NJ USA 08903 New Jersey, New Brunswick, NJ 08903 USA
Titolo Testata:
CLINICAL CANCER RESEARCH
fascicolo: 9, volume: 7, anno: 2001,
pagine: 2601 - 2604
SICI:
1078-0432(200109)7:9<2601:TPAPVO>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITIVE BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; C-ERBB-2 ANTIGEN LEVELS; OVARIAN-CANCER; TAMOXIFEN RESISTANCE; EXTRACELLULAR DOMAIN; ESTROGEN-RECEPTOR; ADJUVANT THERAPY; CARCINOMA-CELLS; HER-2/NEU;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Hait, WN UMDNJ, Robert Wood Johnson Med Sch, Dept Med, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA UMDNJ 195 Little Albany St New Brunswick NJ USA 08903 J 08903 USA
Citazione:
W.N. Hait, "The prognostic and predictive values of ECD-HER-2", CLIN CANC R, 7(9), 2001, pp. 2601-2604

Abstract

The search for a simple, sensitive test to reliably determine prognosis and predict response to therapy in patients with cancer is an important area of translational research. In this issue of Clinical Cancer Research, Hayeset al. (Clin. Cancer Res., 7: 2703-2710, 2001) report the results of an ancillary Cancer and Leukemia Group B protocol designed to determine whether the circulating extracellular domain of HER-2/neu (ECD-HER-2) was indicative of prognosis or predictive of response to therapy in women with metastatic breast cancer. Results were drawn from a sample of 242 patients of whom 89 had elevated values of the protein. These women had been enrolled in a variety of Cancer and Leukemia Group B protocols evaluating either the efficacy of dose in the use of megestrol acetate as second-line hormonal treatment or in patients enrolled into several chemotherapeutic protocols, many containing doxorubicin. They report that patients with pretreatment elevation of ECD-HER-2 had a worse prognosis than those who did not, but that there was no convincing correlation of elevated ECD-HER-2 with response to either endocrine or chemotherapy. Although the small number of patients and the retrospective study design allows one to draw only tentative conclusions, this report raises several important issues for the conduct of translational research and points to several new hypotheses for future testing.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/21 alle ore 02:55:50